| Literature DB >> 26283776 |
Sara A S Dekking1, Rieke van der Graaf1, Martine C de Vries2, Marc B Bierings3, Johannes J M van Delden1, Eric Kodish4, John D Lantos5.
Abstract
In the United States, doctors generally develop new cancer chemotherapy for children by testing innovative chemotherapy protocols against existing protocols in prospective randomized trials. In the Netherlands, children with leukemia are treated by protocols that are agreed upon by the Dutch Childhood Oncology Group. Periodically, the Dutch Childhood Oncology Group revises its protocols. Sometimes, these revisions are categorized as research, sometimes as treatment. In this Ethics Rounds, we analyze whether enrollment in a new protocol ought to be considered research and, if so, we discuss the implications of that designation. Our discussion highlights the different ways different countries approach complex issues of research ethics.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26283776 PMCID: PMC4893943 DOI: 10.1542/peds.2014-2327
Source DB: PubMed Journal: Pediatrics ISSN: 0031-4005 Impact factor: 7.124